Charles River Laboratories International, Inc.’s Stock Price Takes a Dip at $161.35, Recording a 3.37% Decline

Charles River Laboratories International, Inc. (CRL)

161.35 USD -5.63 (-3.37%) Volume: 0.93M

Charles River Laboratories International, Inc.’s stock price stands at 161.35 USD, experiencing a decline of -3.37% this trading session with a trading volume of 0.93M, reflecting a year-to-date (YTD) percentage change of -12.59%, highlighting the need for potential investors to monitor CRL’s market performance closely.

Latest developments on Charles River Laboratories International, Inc.

Charles River Laboratories International Inc. stock had a mixed performance on Tuesday, underperforming compared to its competitors. However, recent collaboration with Valo Health to identify the first lupus treatment candidate using the Logica AI platform has sparked investor interest. This innovative approach showcases the company’s commitment to advancing diagnostics and pharmaceutical research. With this exciting development, Charles River Laboratories International Inc. (CRL) emerges as one of the best diagnostics stocks to invest in right now, positioning itself for potential stock price movements in the near future.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. is looking at a promising long-term outlook based on the Smartkarma Smart Scores. With a strong momentum score of 4, the company is showing positive signs of growth and potential. While the dividend score is lower at 1, indicating lower returns for investors in that aspect, the overall outlook remains optimistic. Charles River Laboratories provides essential research tools and support services for drug discovery, making it a key player in the pharmaceutical and biotechnology industry.

Despite some areas for improvement such as the growth and resilience scores of 2, Charles River Laboratories continues to be a valuable resource for pharmaceutical and biotech companies, hospitals, and academic institutions. The company’s value score of 3 further solidifies its position in the market. Overall, the company’s focus on providing animal research models for new drugs, devices, and therapies positions it well for long-term success in the industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma